Study summary · research use only
Cathelicidin peptide LL-37: A multifunctional peptide involved in heart disease
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This review discusses cathelicidin peptide LL-37, an endogenous peptide best known for its antimicrobial properties, in the context of heart disease. The authors describe LL-37 as having roles in the regulation of atherosclerosis, thrombosis, inflammatory responses, and cardiac hypertrophy, and note that engineered LL-37-related peptides have been developed to study disease regulation. The review summarizes LL-37's biological functions and their relevance to heart disease pathogenesis, aiming to inform future research directions.
Abstract
Heart disease is a common human disease with high morbidity and mortality. Timely and effective prevention and treatment is an urgent clinical problem. The pathogenesis of heart disease is complex and diverse, involving hypertension, diabetes, atherosclerosis, drug toxicity, thrombosis, infection and other aspects. LL-37, an endogenous peptide, is well known for its antimicrobial properties. In recent years, LL-37 has been found to have a variety of biological functions, including its role in the regulation of atherosclerosis, thrombosis, inflammatory responses, and cardiac hypertrophy. Engineered LL-37-related peptides were developed and proved to regulate the development of disease, which revealed its potential clinical application. A comprehensive review and summary of LL-37 is presented to clarify its role in heart disease and to provide a reference and direction for future research.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.